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A premature termination codon (PTC) in the ORF of an mRNA
generally leads to production of a truncated polypeptide, accelerated
degradation of the mRNA, and depression of overall mRNA ex-
pression. Accordingly, nonsense mutations cause some of the most
severe forms of inherited disorders. The small-molecule drug ataluren
promotes therapeutic nonsense suppression and has been thought to
mediate the insertion of near-cognate tRNAs at PTCs. However, direct
evidence for this activity has been lacking. Here, we expressed
multiple nonsense mutation reporters in human cells and yeast
and identified the amino acids inserted when a PTC occupies the
ribosomal A site in control, ataluren-treated, and aminoglycoside-
treated cells. We find that ataluren’s likely target is the ribosome and
that it produces full-length protein by promoting insertion of near-
cognate tRNAs at the site of the nonsense codon without apparent
effects on transcription, mRNA processing, mRNA stability, or protein
stability. The resulting readthrough proteins retain function and con-
tain amino acid replacements similar to those derived from endoge-
nous readthrough, namely Gln, Lys, or Tyr at UAA or UAG PTCs and
Trp, Arg, or Cys at UGA PTCs. These insertion biases arise primarily
frommRNA:tRNAmispairing at codon positions 1 and 3 and reflect, in
part, the preferred use of certain nonstandard base pairs, e.g., U-G.
Ataluren’s retention of similar specificity of near-cognate tRNA inser-
tion as occurs endogenously has important implications for its general
use in therapeutic nonsense suppression.
nonsense suppression | readthrough | Translarna | base mispairing
Nonsense mutations are responsible for ∼10–15% of the single-base-pair mutations that cause human disease, with some
disease genes having considerably higher nonsense mutation fre-
quencies (1). Patients with genetic disorders attributable to non-
sense mutations tend to have more serious ramifications than those
with missense mutations, presumably because of marked reductions
in specific gene expression. Because all diseases caused by nonsense
mutations share the same key gene expression problems, namely
premature translation termination and accelerated mRNA decay,
therapeutic approaches to these problems are being investigated,
with the understanding that a single drug has the potential to treat a
large number of different disorders (1, 2). Normally, the in-frame
UAG, UAA, and UGA codons that arise in mRNA from nonsense
mutations serve as signals for translation termination, but this role
can be functionally overridden by alterations in the translation
machinery or by the presence of certain small molecules that com-
promise the fidelity of translation termination (1, 2). Such nonsense
suppression, or nonsense codon readthrough, by a ribosome en-
gaged in peptide elongation has been predominantly observed in the
context of premature termination codons (PTCs) and is thought to
reflect ribosomal A site acceptance of a near-cognate tRNA and
subsequent incorporation of an amino acid into the nascent poly-
peptide at the position of the PTC (1, 2).
The small-molecule drug ataluren (3-[5-(2-fluorophenyl)-1,2,4-
oxadiazol-3-yl]-benzoic acid; also known as Translarna or PTC124)
is being evaluated both preclinically and clinically for its ability to
promote therapeutic nonsense suppression (1, 3). To date, ataluren
has been shown to restore function to more than 20 different
disease-specific or reporter nonsense alleles in systems ranging in
complexity from in vitro translation to cell culture to mouse models
and human patients (1, 3–14). In the latter, Translarna clinical
trials have demonstrated restoration of full-length functional pro-
tein in Duchenne muscular dystrophy and cystic fibrosis nonsense
mutation patients (10, 11, 13, 15, 16). However, a lack of activity
has been reported for some cell systems (17, 18).
Here, we have investigated the mechanistic basis of PTC read-
through induced by ataluren in human and yeast cells and compared
it to the activity of two other readthrough-promoting compounds,
the aminoglycosides G418 and gentamicin. Using multiple reporters
and a physiologically relevant CFTR (cystic fibrosis transmembrane
conductance regulator) nonsense allele, we have determined the
nature of the translation events at PTCs when cells are treated with
these drugs. Our study provides comprehensive characterization of
the products of PTC readthrough and elucidates the nature of the
nonstandard codon:anticodon base pairings that are favored under
physiological conditions in the cell. These proof-of-concept
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experiments establish unambiguously that these compounds
promote insertion of near-cognate tRNAs at PTCs and provide
insight into the likelihood of functionality for the products of
therapeutic nonsense suppression.
Results
Ataluren Promotes Nonsense Suppression in Mammalian Cells and Yeast.
Six different PTC reporter genes, including some with multiple al-
leles, were used to monitor different aspects of nonsense codon
readthrough in human cells and yeast (SI Appendix, Fig. S1). PTC-
containing transcripts arising from selected reporters are substrates
for nonsense-mediated mRNA decay (SI Appendix, Fig. S2). Ataluren
treatment of mammalian 293H cells stably transfected with wild-type
(WT) or PTC(W12X)-containing NanoLuc (19) reporters promoted
a bell-shaped dose–response, with a peak ninefold increase in lucif-
erase activity derived from the PTC reporter at 10 μM (Fig. 1). This
result was attributable to readthrough of the reporter mRNA’s pre-
mature UGA codon, and not protein stabilization (18), because
ataluren treatment of 293H cells stably expressing WT NanoLuc had
no effect on NanoLuc activity (Fig. 1B). In SI Appendix, Fig. S3A and
B demonstrate that ataluren (and G418) also promote readthrough
of different p53 UGA alleles in Calu6 and HDQ cells and of a UGA
PTC in an H2B-GFP reporter (6) expressed in 293H cells.
Yeast WT [PSI−] cells devoid of the prion form of Sup35
(to ensure that the readthrough observed was solely attribut-
able to drug treatment) showed ataluren-dependent increases
in readthrough from the HA-HIS3(UAA100)-SF or HA-LUC(UGA20)-SF
reporter mRNAs without concomitant changes in mRNA levels al-
beit at higher concentrations than used for mammalian cells, a dif-
ference probably attributable to the yeast cell membrane (Fig. 1C; SI
Appendix, Figs. S2 A and B and S4). This indicated that ataluren
treatment directly affected reporter protein abundance, not alter-
ations in transcription, mRNA processing, or mRNA stability. In
cycloheximide chase assays, ataluren treatment also did not change
the half-life of the full-length His3 readthrough protein, indicating
that the drug affects PTC readthrough per se (SI Appendix, Fig. S5).
Consistent with this conclusion, the prematurely terminated His3
polypeptide fragment that is detectable only by its N-terminal tag in
upf1Δ cells (20) decreases in abundance as synthesis of the full-length
His3 product increases (Fig. 1C, Top; see “His3 PTC” in DMSO and
ataluren lanes in upf1Δ cells).
Near-Cognate tRNAs Facilitate Ataluren-Mediated Readthrough. We
identified the amino acids inserted at PTCs in drug-treated cells
using a firefly luciferase (LUC) reporter system that yields highly
purified readthrough products and well-resolved peptides suit-
able for mass spectrometry and amino acid sequence determi-
nation (SI Appendix, Fig. S1C) (21). It has been suggested that
ataluren is an inhibitor of firefly luciferase and that its reported
nonsense suppression activity simply reflects stabilization of the
luciferase enzyme (18, 22). We consider this claim to be spurious
because (i) ataluren-mediated readthrough has been observed in
numerous other systems (Fig. 1 and SI Appendix, Fig. S3) (1–14,
23); (ii) the effects on luciferase activity could not be indepen-
dently replicated by others (24) or by us (SI Appendix, Fig. S3C);
(iii) ataluren’s putative luciferase inhibitory activity depends on a
specific enzyme substrate (25); and (iv) most of the hypothetical
inhibitory molecule, PTC124-AMP (22), is rapidly converted to
the active readthrough molecule PTC124 (ataluren) under con-
ditions of in vitro translation (SI Appendix, Fig. S6). Accordingly,
three of the HA-LUC(PTC20)-SF reporters were separately ex-
pressed in yeast WT [PSI−] cells. Strep-Tactin purification of the
respective readthrough products synthesized in the absence or
presence of ataluren was monitored by gel electrophoresis to re-
solve full-length proteins (SI Appendix, Fig. S7). Following silver
staining of the gel, the band corresponding to full-length luciferase
protein was excised and subjected to endo-LysC digestion and
LC-MS/MS analysis, and amino acid insertion frequencies were
determined as described previously (21). Analysis of the read-
through products purified from untreated cells showed the in-
corporation of Gln, Lys, and Tyr at UAA and UAG and insertion
of Trp, Arg, and Cys at UGA, all of which were similar to results
reported previously for endogenous background readthrough (Fig.
2A) (21, 26). Readthrough products purified from cells treated
with ataluren showed that Gln, Lys, and Tyr were also inserted
when UAA was the PTC (Fig. 2A). Three independent experi-
ments revealed that the frequencies of insertion of Tyr and Gln
were comparable (51.5 ± 2% and 46.4 ± 2%, respectively) and
that Lys was inserted at a much lower frequency (2 ± 1.7%) (Fig.
2A). Readthrough fromUAG resulted in the insertion of the same
sets of amino acids, but with different frequencies. Gln insertion
predominated, with a frequency of 88 ± 3.6%, whereas Tyr (8.6 ±
2%) and Lys (3.3 ± 1.5%) had somewhat similar insertion fre-
quencies (Fig. 2A). With UGA as the PTC, ataluren treatment
resulted in the incorporation of Trp, Arg, and Cys, with Trp in-
sertions occurring at a much higher frequency (86.3 ± 3%) than
those of Arg (4.6 ± 2%) or Cys (9 ± 2%) (Fig. 2A). A comparison
of the endogenous readthrough events with those mediated by
ataluren indicates that there are no major differences in the re-
spective amino acid insertion frequencies in yeast cells.
In contrast to the results obtained when readthrough was pro-
moted by ataluren, treatment of [PSI−] yeast cells with 7.5 μM
G418 showed a significantly different amino acid insertion profile
for two (UAG and UGA) of the three PTCs (SI Appendix, Table
S1). With UAA as the PTC, the average of two independent ex-
periments showed that the amino acid insertion pattern was similar
to all other readthrough-inducing conditions with relatively com-
parable insertion frequencies of Gln (46.1%) and Tyr (51.8%) and
a low insertion rate for Lys (1.9%) (Fig. 2A; SI Appendix, Table S1).
With UGA as the PTC, insertion of the same amino acids (Trp,
Arg, and Cys) was observed, but, compared with either endogenous
readthrough events or ataluren treatment, significantly higher levels
of Cys insertion (27.2%) were observed (Fig. 2A; SI Appendix, Table
S1). Surprisingly, the amino acid insertion pattern at UAG was
atypical after G418 treatment, with identification of 12 different
amino acids at the PTC, some of which were inserted at very low
levels (SI Appendix, Table S1). Lys was the predominant insertion at
UAG with a frequency of 90% (SI Appendix, Table S1). Gln and
Tyr, the other two amino acids that were normally inserted with
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Fig. 1. Ataluren treatment of mammalian or yeast cells increases PTC read-
through. Dose–response of ataluren treatment in 293H cells stably transfected
with (A) PTC(UGAW12X) or (B) wild-type (WT) NanoLuc reporters. The 293H cells
stably expressing the NanoLuc reporters were treated with ataluren at the in-
dicated concentrations. The data are expressed as themean ± SD of the NanoLuc
activity units normalized to total protein. (C) Western analyses of yeast cells
showing readthrough products expressed from HA-HIS3(UAA100)-SF reporters af-
ter ataluren or gentamicin treatment. Upper and Lower blots, respectively, were
probed for the HA (N-terminal) and FLAG (C-terminal) epitopes. The pre-
dominant band at ∼17 kDa in the HA blot is an HA artifact detected only in cells
expressing HIS3(UAA100)-SF, but not HIS3(WT)-SF.
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much higher frequencies under all other conditions, were detected
after G418 treatment, but with much lower frequencies of 4.7% and
1.5%, respectively (SI Appendix, Table S1). Treatment of cells with
a higher concentration of G418 (15 μM) resulted in insertion of
various amino acids at all three PTCs (SI Appendix, Table S2).
We next tested whether ataluren promoted insertion of similar
sets of near-cognate tRNAs when HA-LUC(PTC20)-SF alleles were
expressed in human cells. As expected, 293H cells stably expressing
HA-LUC(PTC20)-SF alleles manifested increases in luciferase pro-
tein and activity after incubating the cells with ataluren or G418,
and for all combinations other than UAA and ataluren these in-
creases were clearly dependent upon the presence of a PTC in the
luciferase allele (SI Appendix, Fig. S3 C and D). Luciferase read-
through products were purified and subjected to LC-MS/MS anal-
yses as described above. Endogenous readthrough products purified
from cells treated with 0.02% DMSO showed incorporation of two
amino acids when UAA was the PTC: Gln (32.4 ± 8.9%) and Tyr
(67.5 ± 8.9%) (Fig. 2B). When UAG was the PTC, Tyr (73.1 +
15%), Gln (25.2 ± 13.7%), and Trp (1.3 ± 1.4%) were inserted
(Fig. 2B). Surprisingly, the decoding of UAG by Trp-tRNA is in-
dicative of mispairing at the second position of the nonsense codon
(SI Appendix, Table S3), a phenomenon not seen with yeast re-
porters or with the other two nonsense codons in these cells.
Analysis of UGA endogenous readthrough products revealed in-
sertion of Trp (41.4 ± 2.3%) and Arg (58.6 ± 2.3%) (Fig. 2B).
Characterization of readthrough products from 293H cells
treated with ataluren (30 μM) showed insertion of Tyr (57.9 ±
11.3%) and Gln (39.9 ± 11.7%) at UAA; insertion of Tyr (43.9 ±
20.9%), Gln (53.2 ± 20.3%), and Trp (1.8 ± 1.9%) at UAG; and
insertion of Arg (69.7 ± 11.3%), Trp (28.8 ± 11.4%), and Cys
(0.7 ± 0.7%) at UGA (Fig. 2B). For UAA and UAG, the ataluren-
induced readthrough products were similar to the endogenous
readthrough products in identity and relative insertion frequencies
for the respective amino acids. UGA readthrough products from
ataluren-treated cells showed a low but consistent frequency of Cys
insertion that was not observed in the endogenous readthrough
products. Treatment of human cells with another small-molecule
readthrough effector, G418 (150 μM), resulted in the insertion of
Tyr (47.9 ± 14.1%) and Gln (52 ± 14.2%) at UAA; Gln (86.5 ±
8.3%), Tyr (10.8 ± 7.0%), and Lys (2.0 ± 0.8%) at UAG; and Arg
(64.5 ± 11.8%), Trp (17.9+6.8%), and Cys (17.7 ± 8.0%) at UGA
(Fig. 2B). Thus, G418 treatment yielded a pattern and frequency of
amino acid insertion that differed significantly from endogenous
readthrough, with the greatest difference at the UAG PTC, fol-
lowed by UGA, and then UAA. Comparisons to endogenous
readthrough indicated that G418 altered PTC decoding in both
yeast and human cells and in part may reflect G418’s interference
with the decoding process (1, 27). This was found to be true for
another aminoglycoside readthrough effector, gentamicin, in both
yeast (21) and human cells (SI Appendix, Table S4).
Readthrough Products Are Functional.We used three approaches to
determine whether the readthrough products synthesized after
ataluren or aminoglycoside treatment result in functional proteins.
First, the growth of yeast cells harboring the HA-HIS3(UAA100)-SF
allele was monitored when media lacking histidine was or was not
supplemented with readthrough-promoting drugs. In SI Appendix,
Fig. S8A shows that cell growth was restored after ataluren (or
gentamicin) treatment, demonstrating that the amino acids inserted
at the HA-HIS3(UAA100)-SF PTC result in functional readthrough
products. Second, we assessed the functionality of ataluren-induced
luciferase readthrough products by replacing the WT glycine resi-
due at position 20 with the six different amino acids identified in the
yeast-based mass spectrometry analyses of Fig. 2A. These com-
parisons demonstrated comparable activity from all position 20
substitutions (SI Appendix, Fig. S8B), indicating that, at least with
respect to luciferase position 20, enzymatic activity is unlikely to be
affected by ataluren- or G418-mediated readthrough. Finally, we
determined whether protein produced via readthrough therapy
from a disease-causing nonsense allele could also retain function.
Recognizing that G542X is the most frequent CFTR nonsense
mutation (28), we used that allele to test this possibility. CFTR is a
large, hydrophobic protein of generally low abundance, the ex-
pression of which is normally limited to epithelial cells. Because
previous studies have shown that the local sequence context around
a PTC acts as a primary determinant of readthrough efficiency (29,
30), we inserted the CFTR-G542X mutation (TGA) and its local
sequence context (three codons on either side) into a construct
amenable to protein purification from HEK293 cells and mass
spectrometry. This construct contained TGFP, the CFTR-G542X
mutation and context, and C-terminal HA and 6× His tags (SI
Appendix, Fig. S1D). After PTC suppression, the full-length protein
will contain TGFP, along with the HA and His tags, whereas the
prematurely terminated protein will contain TGFP only. We ob-
served an increase of full-length protein production after G418
(150 μM) treatment of HEK293 cells harboring this reporter (Fig.
3A) and then identified the amino acids inserted at the PTC of the
TGFP-CFTR-542X mRNA with G418 treatment. Consistent with
the data obtained from LUC reporters in yeast and 293H cells, the
same three amino acids (Arg, Cys, and Trp) were identified in this
UGA suppression reporter system, but with different frequencies
(SI Appendix, Fig. S9 and Table S5).
We then determined if these amino acid substitutions affected
CFTR function. Site-directed mutagenesis was used to change the
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Fig. 2. Ataluren-mediated decoding of nonsense
codons. Comparison of amino acid insertion at PTCs
during termination readthrough of HA-LUC(PTC20)-
SF reporters after ataluren treatment in yeast and
293H cells. Epitope-tagged luciferase was purified
from the respective cells and subjected to mass
spectrometry analyses. Box and whisker graphs
depict the amino acids inserted for each nonsense
codon. Horizontal lines are the means and vertical
lines are the SD. (A) Data from WT [PSI−] yeast cells
treated with 30 μM ataluren (n = 3). (B) Data from
293H cells treated with 30 μM ataluren. Boxes rep-
resent the range of at least four determinations.
Where there are no boxes, three determinations
were done. Data used to generate graphs in B are in
SI Appendix, Table S6.
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position 542 Gly codon to Arg, Cys, or Trp codons in a full-length
cDNA. Transient transfections were then used to introduce each
construct into HEK293 cells, and the core glycosylated (band B) and
mature (band C) forms of CFTR were visualized by Western blot-
ting (Fig. 3B). We found that the cell lines expressing the G542R
and G542C forms of CFTR exhibited less maturation of band B to
band C thanWT CFTR, whereas the G542W cell line did not exhibit
any band C. These results suggest that these three CFTR variants at
position G542 either cause a partial defect in maturation of the en-
doplasmic reticulum (ER) form of CFTR to the mature cell-surface
form or reduce the stability of the mature form of CFTR at the cell
surface (Fig. 3B). To address these potential defects at the functional
level, we constructed stable cell lines by transfecting the WT CFTR,
CFTR-G542X, G542R, G542C, or G542W constructs into Fischer
rat thyroid (FRT) cells, a cell type for which the conditions required
for cell growth, PTC readthrough, and electrophysiological assays
were compatible with G418 treatment. Using these stable FRT cell
lines grown to confluence on filters, we performed short-circuit cur-
rent (Isc) and transepithelial chloride conductance (Gt) assays to
measure CFTR function. Forskolin was used to activate CFTR, and
the CFTR inhibitor CFTRInh-172 was used to confirm the specificity
of CFTR function. To correct for any differences in CFTR expres-
sion, these measurements were then normalized to theCFTRmRNA
level measured in each stable cell line by qPCR analysis. As expected,
all three G542 substitutions displayed lower CFTR activity than WT
(Fig. 3 C and D). G542R and G542C showed ∼40–70% of WT Isc,
which correlates well with less band C (Fig. 3B). We measured a
corrected CFTR activity of only ∼10% for G542W, consistent with
little or no band C observed in the Western blot. Taken together,
these results demonstrate that CFTR variants resulting from
readthrough retain variable but significant functionality.
Rules of Near-Cognate tRNA Insertion. With the exception of some
aspects of G418-mediated nonsense suppression treatment, which
may be atypical (see above), a comparison of the amino acids
inserted at PTCs under different readthrough-inducing conditions,
as well as with different reporters, shows considerable similarity in
yeast and mammalian cells. In both organisms, Gln, Lys, and Tyr
are inserted at UAA and UAG, and Trp, Arg, and Cys are
inserted at UGA (Fig. 2; SI Appendix, Tables S1, S2, S4, and S6)
(21, 26). Our analyses of readthrough products indicate that such
biases arise, in part, because some nonstandard codon:anticodon
base pairs are preferred over others (SI Appendix, Table S3). For
example, in all instances where individual tRNA choices can be
identified, position 1 U-G mispairing appears to be preferred over
U-U (Fig. 2; SI Appendix, Tables S1, S2, S4, and S6) (21). Fur-
thermore, the lack of Gly insertion at UGA and Gln insertion at
UAA or UAG (with the exception of G418 treatment) suggests
that U-C mispairing at position 1 of the codon is not readily ac-
commodated. Given that the decoding center of the ribosome is
geometrically constrained (31, 32), the structure of the base pairs
might be key determinants of mispairing. Alternatively, the relative
abundance of tRNAs may govern insertion frequencies. To assess
whether favored geometry of certain base pairs or tRNA abundance
is the key parameter for this bias, we examined tRNA utilization in
UGA readthrough. When UGA is the PTC, yeast cells show pref-
erential insertion of Trp whereas 293H cells prefer insertion of Arg
(Fig. 2 A and B). Arg insertion at UGA can be mediated by two
near-cognate tRNAs: tRNA-Arg-UCG (using U-G mispairing at
position 1 of the codon) and tRNA-Arg-UCU (using U-U mis-
pairing at position 1 of the codon) (SI Appendix, Table S3). In yeast,
Arg insertion at UGA most likely occurs by mispairing of tRNA-
Arg-UCU, as tRNA-Arg-UCG expression has not been observed in
these cells (33). On the other hand, tRNA-Arg-UCG is expressed in
mammalian cells (33), and their insertion of Arg could be mediated
via either of the Arg near-cognate tRNAs. We introduced and
overexpressed a recombinant tRNA-Arg-UCG in WT [PSI−] yeast
cells and monitored the insertion of Arg in the readthrough prod-
ucts. As a control, we overexpressed the endogenous tRNA-
Arg-UCU. Northern analyses of total RNA isolated from the cells
overexpressing the corresponding tRNA-Arg plasmids show con-
siderable and comparable overexpression of the respective tRNA-
Arg species (SI Appendix, Fig. S10A). A comparison of the luciferase
activity from these strains showed that cells expressing tRNA-Arg-
UCG also showed increased luciferase activity (SI Appendix, Fig.
S10B), indicating that the expression of this specific tRNA correlated
with enhanced readthrough efficiency. Moreover, expression of the
recombinant tRNA-Arg-UCG shifted the bias toward Arg insertion
at a frequency of 89.3 ± 1.5%, in contrast to a frequency of 6.6 ± 3%
in WT cells (SI Appendix, Fig. S10C). In comparison, overexpression
of the endogenous tRNA-Arg-UCU in yeast cells increased the
frequency of Arg insertion to 30.6 ± 4.7% (SI Appendix, Fig. S10C).
These observations are consistent with the notion that U-G codon:
anticodon mispairing is favored over U-U mispairing in position 1.
We also tested whether a U-C codon:anticodon mispairing event
can be introduced at position 1 by overexpressing the corresponding
near-cognate tRNA, tRNA-Glu-UUC. Even though strains over-
expressing tRNA-Glu-UUC showed increased levels of the tRNA
species compared withWT (SI Appendix, Fig. S10D), the readthrough
efficiency, as monitored by luciferase activity, was not altered (SI
Appendix, Fig. S10E), and the readthrough products from those cells
showed insertion of the same three amino acids; i.e., Glu insertion
was still not observed (SI Appendix, Fig. S10F). Taken together, these
data suggest that some nonstandard base pairs are favored over
others for near-cognate tRNA insertion at PTCs and that the ge-
ometry of the base pairs is the most likely determinant of this bias.
The Ribosome as a Likely Target of Ataluren. In a recent clinical trial
(12), cystic fibrosis patients with nonsense mutations failed to show a
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Fig. 3. Characterization of the amino acid insertions at human CFTR-G542X.
(A) Western blot showing an increased amount of full-length protein (con-
taining both TGFP and HA tag) (yellow-green bands) compared to the TGFP
protein lacking the HA tag (red bands) after G418 treatment in HEK293 cells
transiently transfected with the G542X construct. (B) Western blot showing the
level of CFTR maturation observed in HEK293 cells transiently transfected with
CFTR G542 variants. “Band B” is the ER form of CFTR, whereas “Band C” is the
mature form. CFTR-F508del is a mutant form of CFTR that is retained in the ER
and consequently only produces Band B. (C) Representative tracings (Left) and
quantitation results (Right) of short-circuit current (Isc) measurements of CFTR
chloride channel activity in FRT epithelial cell monolayers stably expressing the
CFTR G542 variant constructs. (D) Representative tracings (Left) and quantita-
tion (Right) of Conductance (Gt) measurements of CFTR chloride channel ac-
tivity in FRT monolayers stably expressing the CFTR G542 variant constructs.
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significant response to ataluren if they were concurrently being
treated with inhaled tobramycin, an aminoglycoside with strong af-
finity for the ribosomal A site (34). This observation suggested that
tobramycin might be an inhibitor of ataluren’s nonsense suppression
activity, a possibility considered in the experiments of Fig. 4. In
HEK293 cells, stably expressing the W12X NanoLuc reporter treat-
ment with a wide range of tobramycin concentrations failed to elicit
any detectable readthrough activity of the drug (Fig. 4). However, in
cells manifesting substantial ataluren-mediated readthrough of the
PTC-containing NanoLuc mRNA, addition of tobramycin showed
strong, dose-dependent reduction of ataluren’s readthrough activity
(Fig. 4), consistent with previous work showing that aminoglycosides
reduce the ability of ataluren to promote readthrough but non-
aminoglycoside antibiotics have no effect (12). Quantitation of this
effect indicated that tobramycin inhibition of ataluren’s activity had
an IC50 of 20 μM (Fig. 4). These results not only provide insight into
the results of the aforementioned clinical trial, but also suggest that
ataluren, like tobramycin, might also bind to the ribosome and thus
affect near-cognate tRNA selection during readthrough.
Discussion
Therapeutic nonsense suppression is a potentially powerful ap-
proach to the treatment of the large number of genetic disorders
caused by nonsense mutations, and several small-molecule drugs
are being investigated for their capability to engender such therapy
(1, 2). Multiple experimental approaches with cell lines, patient
cells, animal models, and genetic disorder patients have demon-
strated that the drug ataluren can restore expression to genes and
mRNAs otherwise inactive because of the presence of premature
nonsense codons (1, 3–14, 23). Collectively, such experiments have
strongly suggested that ataluren promotes nonsense suppression,
i.e., the insertion of near-cognate tRNAs at PTCs, but direct evi-
dence for this activity has been lacking. Here, we determined the
amino acid sequences of full-length LUC and chimeric CFTR
proteins accumulating in control and readthrough effector-treated
yeast and human cells, an approach that leads us to conclude that
ataluren does indeed stimulate the incorporation of near-cognate
tRNAs at PTCs. Notably, our analysis of the products of ataluren-
induced PTC readthrough demonstrates that a distinct subset of
amino acids is inserted during nonsense suppression of reporter and
disease-related mRNAs in human cells. These results, the obser-
vation that the amino acid insertions occurring as a consequence of
ataluren treatment are similar but not identical to those occurring
endogenously (Fig. 2), and the finding that tobramycin specifically
antagonizes the restoration of NanoLuc activity from a PTC allele
by ataluren (Fig. 4) negate other hypotheses that sought to explain
ataluren’s mechanism of action (17, 18).
Ataluren’s enhancement of near-cognate tRNA insertion favors a
subset of tRNAs, generally leading to incorporation of Gln, Lys, and
Tyr at UAA and UAG codons and of Trp, Arg, and Cys at UGA
codons. The weak readthrough activity seen here with the HA-
LUC(UAA20)-SF allele is atypical of that seen with UAA PTCs in
other mRNAs (3, 4, 14) and most likely reflects the influence of
codon context on readthrough (29). Ataluren’s influence over the
extent of specific tRNA selection implies that this drug’s target
could be the ribosome, a conclusion consistent with the drug’s
markedly diminished efficacy in the presence of tobramycin (Fig. 4),
an aminoglycoside known to bind to the ribosome’s A site (34). The
apparent tRNA selection bias also suggests that both endogenous
and ataluren-stimulated near-cognate tRNA mispairing are not
random processes and that factors contributing to the apparent
preferences are conserved. One component of this selection process
is a set of favored mispairings, primarily at codon position 1, where
U-G mispairing is preferred over U-U and where U-C mispairing is
strongly disfavored (Fig. 2; SI Appendix, Table S3) (21). As noted
previously (21), U-G mispairing at position 1 is likely to be favored
because of its ability to act as a geometric mimic of a U-A base pair
(32). It is also plausible that the stability of nonstandard base pairs
in position 1 is enhanced by modification of neighboring tRNA
anticodon bases, e.g., thiolation of the wobble position uridine (35).
At position 3, multiple nonstandard mispairings are tolerated
including A-C, G-G, A-G, and possibly others (Fig. 2; SI Ap-
pendix, Table S3) (21). Another determinant of tRNA insertion
choice is the extent to which the tRNA is expressed, if at all. As
shown in the experiments in SI Appendix, Fig. S10C, yeast cells
prefer Trp insertion over Arg insertion at UGA, largely because
they lack tRNA-Arg-UCG, a tRNA that allows U-G mispairing.
When tRNA-Arg-UCG was provided, it both stimulated read-
through and led to a marked increase in the relative frequency of
Arg insertion at the PTC, unlike tRNA-Arg-UCU overexpression
(SI Appendix, Fig. S10C) (36).
An important observation from these experiments is that the
readthrough products of ataluren- or aminoglycoside-mediated
nonsense suppression tested here are at least partially functional
and, in many cases, fully functional. Earlier experiments with re-
porter genes, cultured cells, mouse models, and clinical trials of
human DMD and CF nonsense mutation patients indicated that
readthrough products are functional (1, 3–13, 23, 37–39), but could
not address the question of specific amino acid substitutions at
specific codon positions. Although our studies have addressed sub-
stitutions in only a limited number of positions in luciferase, His3,
and CFTR, it is nevertheless reassuring with respect to the potential
of therapeutic nonsense suppression that all of the substitutions
analyzed here retained some degree of function. It will be of interest
to determine whether the observed activities can be increased by
parallel approaches, e.g., antagonists of mRNA decay (2), specific
protein correctors or potentiators [as have been successfully used
for CFTR (39)], or enhancers of the expression of certain tRNAs.
The efficacy of therapeutic nonsense suppression will also de-
pend on the relative toxicity of the drug used to promote specific
PTC readthrough. Ataluren has been shown to exhibit a favorable
safety profile (27), and we speculate that at least two aspects of its
activity support this attribute. First, as discussed above, ataluren
stimulates PTC insertion of a set of near-cognate tRNAs that
closely resemble those inserted endogenously at much lower levels.
As a consequence, the full-length proteins that accumulate in ata-
luren-treated cells are unlikely to have antigenic differences from
the repertoire of readthrough proteins normally accumulating in a
patient, albeit at low levels. This low-level expression of full-length
proteins by endogenous readthrough of nonsense-containing
mRNAs may be sufficient to allow the polypeptides that accumulate
during ataluren-stimulated readthrough to be recognized as “self”
by the immune system, thus minimizing the potential for an auto-
immune reaction. Second, at least compared with G418, ataluren
generally has modest readthrough activity, showing only read-
through of premature termination events, but lacking readthrough
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Fig. 4. Tobramycin is a potent inhibitor of ataluren-mediated readthrough.
The effect of tobramycin on NanoLuc activity in HEK293 cells expressing a UGA
(W12X) NanoLuc reporter with either no prior treatment or following treat-
ment with 10 μM ataluren for 48 hours. Initial stimulation of readthrough by
ataluren in the absence of tobramycin was 15-fold above background.
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activity on the considerably more efficient process of normal ter-
mination (3, 40). Ataluren’s failure to promote detectable read-
through of normal termination codons undoubtedly minimizes the
possible accumulation of C-terminally extended proteins and their
likely inhibitory activity and immunogenicity. In this regard, the
much higher readthrough activity of G418, as well as its deviation
from the pattern of endogenous insertion of near-cognate tRNAs,
may contribute to that drug’s known toxicity (2). These results in-
crease our understanding of readthrough therapies and how they
might be tailored to specific disease alleles.
Materials and Methods
Detailed methods, given in SI Appendix, SI Materials and Methods, are
summarized here.
Reporter and Expression Plasmids. LUC- and HIS3-based reporters were used to
analyze readthrough in yeast, and NanoLuc-, H2B-GFP-, p53-, LUC-, and TGFP-
based reporters were used for the same purpose in human cells. For yeast, the
construction and use of epitope-tagged LUC-PTC20 reporters has been described
previously (21); theHIS3-PTC100 reporter used comparable epitope tags. In human
cells, (i) using oligonucleotides DB4084 and DB4085 (SI Appendix, Table S7), UGA
was introduced at codon 12 of the NanoLuc ORF expressed from pFN[Nluc/CMV/
Neo] (Promega); (ii) the H2B-GFP reporter was constructed as described by Lentini
et al. (6); (iii) UGA PTCs at positions 196 or 213 of the p53 ORF were introduced
using site-directed mutagenesis, and the respective constructs were expressed
from pcDNA 3.1 Hygro(+); (iv) LUC-PTC20 constructs used in yeast were modified to
include TPI1 intron 6 at nucleotide 239 and expressed from pSELECT Zeo; (v)
CFTR-G542X (UGA) and CFTR-WT, along with codons 539–541 and 543–545, were
fused to TurboGFP (TGFP) along with HA and 6× His tags and expressed from
pcDNA 3.1 Zeo(+); and (vi) CFTR-G542R, G542C, and G542Wwere created by site-
directed mutagenesis of a WT CFTR cDNA and expressed from pcDNA 3.1 Zeo(+).
RNA and Protein Analyses. Procedures for RNA analysis, protein purification, and
luciferase assays were as described previously (3, 19, 21, 38) or in SI Appendix.
Western analyses and protein purification largely used antibodies or affinity
resins targeted to the HA, FLAG, StrepII, T-GFP, and 6× His epitope tags
expressed from the respective reporter constructs.
Amino Acid Sequence Analysis of Luciferase and GFP-CFTR Readthrough Products.
Luciferase readthrough proteins were purified by epitope tag affinity chro-
matography and gel electrophoresis, subjected to proteolytic digestion, and
analyzed by LC-MS/MS as described previously (21) and in SI Appendix. Raw data
files were subjected to database searches, using SwissProt indices for Saccha-
romyces cerevisiae and human polypeptides. Comparable analyses based on
CFTR used SEQUEST searches and Scaffold Q+.
ACKNOWLEDGMENTS.We are indebted to Elizabeth Grayhack and Christina
Brule for generously providing tRNA expression plasmids and Shirley Yeh and
Angela Esteves for technical support. Thisworkwas supported by National Institutes
of Health Grants R37 GM27757 (to A.J.), R21 NS090928 (to D.M.B.), R21NS090928
(to K.M.K.), and P30 DK072482 (to S.M.R.); by the Cystic Fibrosis Foundation
(D.M.B. and S.M.R.); and by the University of Alabama Institutional Core Support
Program from National Cancer Institute Grant P30CA13148-38 (to J.M.)
1. Peltz SW, Morsy M, Welch EM, Jacobson A (2013) Ataluren as an agent for therapeutic
nonsense suppression. Annu Rev Med 64:407–425.
2. Keeling KM, Xue X, Gunn G, Bedwell DM (2014) Therapeutics based on stop codon
readthrough. Annu Rev Genomics Hum Genet 15:371–394.
3. Welch EM, et al. (2007) PTC124 targets genetic disorders caused by nonsense muta-
tions. Nature 447(7140):87–91.
4. Li M, Andersson-Lendahl M, Sejersen T, Arner A (2014) Muscle dysfunction and
structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by
ataluren treatment. FASEB J 28(4):1593–1599.
5. Gregory-Evans CY, et al. (2014) Postnatal manipulation of Pax6 dosage reverses
congenital tissue malformation defects. J Clin Invest 124(1):111–116.
6. Lentini L, et al. (2014) Toward a rationale for the PTC124 (Ataluren) promoted
readthrough of premature stop codons: A computational approach and GFP-reporter
cell-based assay. Mol Pharm 11(3):653–664.
7. Drake KM, Dunmore BJ, McNelly LN, Morrell NW, Aldred MA (2013) Correction of
nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hyper-
tension. Am J Respir Cell Mol Biol 49(3):403–409.
8. Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K (2011) PTC124-mediated
translational readthrough of a nonsense mutation causing Usher syndrome type 1C.
Hum Gene Ther 22(5):537–547.
9. Sánchez-Alcudia R, Pérez B, Ugarte M, Desviat LR (2012) Feasibility of nonsense mu-
tation readthrough as a novel therapeutical approach in propionic acidemia. Hum
Mutat 33(6):973–980.
10. Haas M, et al. (2015) European Medicines Agency review of ataluren for the treatment of
ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting
from a nonsense mutation in the dystrophin gene. Neuromuscul Disord 25(1):5–13.
11. Bushby K, et al.; PTC124-GD-007-DMD STUDY GROUP (2014) Ataluren treatment of
patients with nonsense mutation dystrophinopathy. Muscle Nerve 50(4):477–487.
12. Kerem E, et al.; Cystic Fibrosis Ataluren Study Group (2014) Ataluren for the treat-
ment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-
controlled phase 3 trial. Lancet Respir Med 2(7):539–547.
13. Finkel RS, et al. (2013) Phase 2a study of ataluren-mediated dystrophin production in pa-
tients with nonsense mutation Duchenne muscular dystrophy. PLoS One 8(12):e81302.
14. Moosajee M, et al. (June 21, 2016) Functional rescue of REP1 following treatment
with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and
the nonsense-mediated zebrafish model. Hum Mol Genet, pii: ddw184.
15. Sermet-Gaudelus I, et al. (2010) Ataluren (PTC124) induces cystic fibrosis trans-
membrane conductance regulator protein expression and activity in children with
nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 182(10):1262–1272.
16. Kerem E, et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by
nonsense mutations: A prospective phase II trial. Lancet 372(9640):719–727.
17. McElroy SP, et al. (2013) A lack of premature termination codon read-through efficacy
of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol 11(6):e1001593.
18. Auld DS, Thorne N, Maguire WF, Inglese J (2009) Mechanism of PTC124 activity in cell-based
luciferase assays of nonsense codon suppression. Proc Natl Acad Sci USA 106(9):3585–3590.
19. Hall MP, et al. (2012) Engineered luciferase reporter from a deep sea shrimp utilizing
a novel imidazopyrazinone substrate. ACS Chem Biol 7(11):1848–1857.
20. Kuroha K, Tatematsu T, Inada T (2009) Upf1 stimulates degradation of the product
derived from aberrant messenger RNA containing a specific nonsense mutation by
the proteasome. EMBO Rep 10(11):1265–1271.
21. Roy B, Leszyk JD, Mangus DA, Jacobson A (2015) Nonsense suppression by near-
cognate tRNAs employs alternative base pairing at codon positions 1 and 3. Proc Natl
Acad Sci USA 112(10):3038–3043.
22. Auld DS, et al. (2010) Molecular basis for the high-affinity binding and stabilization of
firefly luciferase by PTC124. Proc Natl Acad Sci USA 107(11):4878–4883.
23. Zhou Y, Jiang Q, Takahagi S, Shao C, Uitto J (2013) Premature termination codon
read-through in the ABCC6 gene: Potential treatment for pseudoxanthoma elasti-
cum. J Invest Dermatol 133(12):2672–2677.
24. Green L, Goff SP (2015) Translational readthrough-promoting drugs enhance pseu-
doknot-mediated suppression of the stop codon at the Moloney murine leukemia
virus gag–pol junction. J Gen Virol 96(11):3411–3421.
25. Peltz SW, et al. (2009) Nonsense suppression activity of PTC124 (ataluren). Proc Natl
Acad Sci USA 106(25):E64; author reply E65.
26. Blanchet S, Cornu D, Argentini M, Namy O (2014) New insights into the incorporation
of natural suppressor tRNAs at stop codons in Saccharomyces cerevisiae. Nucleic Acids
Res 42(15):10061–10072.
27. Hirawat S, et al. (2007) Safety, tolerability, and pharmacokinetics of PTC124, a non-
aminoglycoside nonsense mutation suppressor, following single- and multiple-dose ad-
ministration to healthy male and female adult volunteers. J Clin Pharmacol 47(4):430–444.
28. Bobadilla JL, Macek M, Jr, Fine JP, Farrell PM (2002) Cystic fibrosis: A worldwide
analysis of CFTR mutations: Correlation with incidence data and application to
screening. Hum Mutat 19(6):575–606.
29. Manuvakhova M, Keeling K, Bedwell DM (2000) Aminoglycoside antibiotics mediate
context-dependent suppression of termination codons in a mammalian translation
system. RNA 6(7):1044–1055.
30. Keeling KM, Bedwell DM (2002) Clinically relevant aminoglycosides can suppress
disease-associated premature stop mutations in the IDUA and P53 cDNAs in a
mammalian translation system. J Mol Med (Berl) 80(6):367–376.
31. Westhof E, Yusupov M, Yusupova G (2014) Recognition of Watson-Crick base pairs: Con-
straints and limits due to geometric selection and tautomerism. F1000Prime Rep 6:19.
32. Demeshkina N, Jenner L, Westhof E, Yusupov M, Yusupova G (2013) New structural
insights into the decoding mechanism: Translation infidelity via a G·U pair with
Watson-Crick geometry. FEBS Lett 587(13):1848–1857.
33. Tuller T, et al. (2010) An evolutionarily conserved mechanism for controlling the ef-
ficiency of protein translation. Cell 141(2):344–354.
34. Salian S, et al. (2012) Structure-activity relationships among the kanamycin amino-
glycosides: Role of ring I hydroxyl and amino groups. Antimicrob Agents Chemother
56(12):6104–6108.
35. Kumar RK, Davis DR (1997) Synthesis and studies on the effect of 2-thiouridine and 4-thio-
uridine on sugar conformation and RNA duplex stability. Nucleic Acids Res 25(6):1272–1280.
36. Beznosková P, Gunišová S, Valášek LS (2016) Rules of UGA-N decoding by near-cog-
nate tRNAs and analysis of readthrough on short uORFs in yeast. RNA 22(3):456–466.
37. Bedwell DM, et al. (1997) Suppression of a CFTR premature stop mutation in a
bronchial epithelial cell line. Nat Med 3(11):1280–1284.
38. Du M, et al. (2008) PTC124 is an orally bioavailable compound that promotes sup-
pression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl
Acad Sci USA 105(6):2064–2069.
39. Xue X, et al. (2014) Synthetic aminoglycosides efficiently suppress cystic fibrosis
transmembrane conductance regulator nonsense mutations and are enhanced by
ivacaftor. Am J Respir Cell Mol Biol 50(4):805–816.
40. Amrani N, et al. (2004) A faux 3′-UTR promotes aberrant termination and triggers
nonsense-mediated mRNA decay. Nature 432(7013):112–118.
6 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1605336113 Roy et al.
1 
 
Supporting Information 
 
SI Materials and Methods 
Readthrough Drugs 
PTC Therapeutics, Inc. supplied ataluren for this study. Ataluren was dissolved in 
dimethylsulfoxide (DMSO) and cultured cells were treated such that the final DMSO 
concentration was 0.3% (vol/vol).  Tobramycin, geneticin (G418), and gentamicin were 
purchased from Sigma and were administered in PBS. 
Plasmid Construction  
a) Yeast expression plasmids 
 i. LUC reporters. Construction and use of epitope-tagged LUC-based PTC20 
reporters has been described previously (1). 
 ii. HIS3 reporter. The wild-type HA-HIS3-SF and the PTC-containing HA-
HIS3(UAA100)-SF constructs consist of the yeast TPI1 promoter followed by an N-terminal 
3X Hemaglutinin (HA) tag fused in-frame with the HIS3 gene (with/without an in-frame 
stop codon at HIS3 position 100), followed by in-frame StrepII and FLAG tags and the 
TPI1 3’ UTR. The plasmids harboring either the wild-type or the PTC-containing HIS3 
cassette were generated by PCR and standard molecular cloning techniques, and 
fragments were inserted into yEplac181 after digestion of the respective restriction sites.  
b) Mammalian expression plasmids 
 i. NanoLuc reporters. The pFN[Nluc/CMV/Neo] plasmid containing the NanoLuc 
open reading frame was purchased from Promega Corporation (CS181701).  Using site-
directed mutagenesis and oligonucleotides DB4084 and DB4085 (Supp. Table 7), a point 
mutation was introduced into NanoLuc at codon 12, which changed the tryptophan codon 
(UGG) to a UGA PTC. Using standard techniques, the WT and W12X NanoLuc open 
reading frames were then subcloned into the NheI and XhoI sites of pcDNA3.1Zeo(-) 
(Invitrogen). These plasmid constructs were subsequently transfected into 293H cells and 
stable transfectants were selected using 0.2 mg/ml zeocin (Invitrogen) for three weeks.   
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 ii. p53 reporters. Alleles of the p53 ORF were synthesized with TGA nonsense 
mutations at positions 196 or 213 and then cloned into pcDNA3.1/Hygro(+) using 
standard techniques. The plasmids were then transfected into either CALU-6 or HDQ cell 
lines.      
 iii. H2B-GFP reporter. This reporter encompasses a histone H2B coding 
sequence fused to that of GFP, with the TGG codon at nucleotide positions 172-174 of 
the GFP ORF mutated to TGA. Construction of the vector was as described by Lentini et 
al. (2)  
 iv. LUC reporters. The luciferase reporter system used for readthrough analyses 
in mammalian cells is similar to the set of yeast luciferase readthrough reporters used in 
Roy et al. (1), with a few modifications. Intron 6 from the yeast TPI1 gene was introduced 
into the LUC coding sequence at nucleotide 239, downstream of the PTC20 insertion site. 
The HA-LUC2-SF cassette (wild-type or PTC-containing) was then cloned into 
corresponding restriction sites in the pSELECT Zeo MCS using standard molecular 
biology techniques.   
 v. TGFP reporter. CFTR-G542X (UGA) or the corresponding wild-type along with 
the G542X context (three codons upstream and downstream) was fused to TurboGFP 
(TGFP) along with HA and 6XHis tags. This fragment was inserted into the pcDNA 3.1 
Zeo(+) expression vector (Invitrogen). CFTR-G542R, G542C, and G542W were obtained 
through site-directed mutagenesis of a wild-type CFTR cDNA. The mutated fragment of 
CFTR was inserted into the CFTR cDNA in pcDNA 3.1 Zeo(+) and sequences were 
confirmed. 
 
Yeast Cell Methods 
a) Protein purification and analyses. Cells expressing HA-LUC-SF or HA-LUC(PTC20)-
SF were grown in synthetic complete (SC) medium lacking leucine with or without any 
drug treatment for readthrough induction. Readthrough products were purified as 
described previously (1). Briefly, cells were collected by rapid filtration and resuspended 
in Buffer W (100 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA; supplemented with 0.1 mM 
DTT, 1 mM PMSF, and 1X protease inhibitor cocktail (Roche)). Cells were lysed using a 
cryoMill (Retsch) at 10 hertz for 20 min with constant liquid nitrogen cooling. Cell lysates 
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were clarified and luciferase was purified using Strep-Tactin resin according to the 
manufacturer’s protocol (IBA, Germany). The efficiency of luciferase purification was 
monitored by analyzing fractions for luciferase activity, as well as by western blot analyses 
using anti-FLAG antibody (Sigma). Elution fractions from Strep-Tactin purification were 
concentrated using Amicon Ultra-15 30K NMWL filters (EMD Millipore) followed by 
analysis on 8% SDS-PAGE to resolve the readthrough product. Gels were silver stained 
(Proteosilver, Sigma) and processed for MS analysis. Three independent experiments 
were performed for all (one codon under one readthrough-inducing condition) except 
G418 treatment for which only two independent experiments were performed.  
b) RNA analyses. Total RNA isolation and northern analyses were performed as 
described previously (1). Cells expressing either HA-LUC-SF or HA-LUC(PTC20)-SF were 
grown in synthetic complete (SC) media lacking leucine. Random-primed DNA probes 
made from the 1.6 Kb NcoI-XhoI luciferase fragment or 129 bp XhoI-XbaI Strep-FLAG 
fragment were used to detect LUC mRNA and HIS3 mRNA, respectively. Random-primed 
DNA probes made from the 0.6 Kb EcoRI-HindIII CYH2 fragment, or the 0.5 Kb EcoRI 
SCR1 fragment were used to detect the CYH2 pre-mRNA, CYH2 mRNA, and the SCR1 
RNA as controls for NMD and normalization, respectively. Transcript-specific signals 
were determined with a FUJI BAS-2500 analyzer. 
 For tRNA expression analysis, total tRNA was isolated from wild-type cells and 
cells overexpressing either tRNA-Arg-UCG (DL869) (3), tRNA-Arg-UCU (ECB1451), or 
tRNA-Glu-UUC (ELH239) as described previously (4). Isolated tRNAs (10 µg per sample) 
were resolved on a 6.5% polyacrylamide-8 M urea-0.1 M NaAc (pH 5.0) gel and 
electroblotted to Zeta-Probe membranes (Bio-Rad). 32P-labeled oligonucleotides 
complementary to the tRNA of interest were used as probes. tRNA-specific signals were 
determined with a FUJI BAS-2500 analyzer. 
c) Western analyses. Yeast cells (0.4 OD600 units per sample) were collected and 
processed as described previously (1). Samples were resolved by SDS-PAGE, 
transferred to Immobilon-P (Millipore) membranes, and incubated with anti-HA antibody 
(Sigma), anti-FLAG antibody (Sigma), or a monoclonal anti-Pgk1 antibody (Molecular 
Probes). 
 
4 
 
d) Protein half-life measurements. Readthrough product half-life was quantified as 
described previously (5). Yeast cells expressing HA-HIS3-SF or HA-HIS3(PTC100)-SF 
reporters were treated with ataluren and were grown in synthetic complete (SC) media 
lacking leucine to log phase. Cycloheximide (50 µg/mL) was added to terminate protein 
synthesis followed by collection of equal number of cells at various time points and 
subjected to western blot analyses.  
 
Mammalian Cell Methods 
a) Protein purification and activity assays 
 i. NanoLuc activity assay.  Prior to performing NanoLuc assays, zeocin was 
omitted from the media of the stable NanoLuc 293H cell lines for two passages due to its 
inhibitory effect on cell growth.  WT and W12X reporter cells were then seeded into 96-
well culture plates at a density of 4 x104 per well. When cells became 50% confluent, 
they were treated with drugs for a period of 48 hours prior to assay.  NanoLuc activity was 
measured using the Nano-Glo Luciferase Assay (Promega, N1110).  All cells expressing 
the NanoLuc constructs were lysed in 50µl of 1X Passive Lysis Buffer (PLB) (Promega, 
E1941).  However, the lysate of WT NanoLuc expressing cells was subsequently diluted 
1:1000 with 1X passive lysis buffer.  In a separate 96-well plate (Fisher 12-566-04), 5µl 
of the Nano-Glo Reagent were mixed with 5µl of each cell lysate and then incubated for 
10 min at room temperature.  Luciferase activity readings were then measured using a 
GloMax Multi Detection System (Promega). The data are expressed as the NanoLuc 
activity generated normalized to micrograms of total protein. 
 ii. Purification and analysis of LUC readthrough products. Wild-type or PTC-
containing LUC expression plasmids were transfected into 293H cells (ThermoFisher 
Scientific) with FuGene 6 (Promega) and stable clones were selected using 300µg/mL 
Zeocin (ThermoFisher Scientific). Cells were harvested 72 hours after 30 µM ataluren 
treatment and 24 hours after 150 µM G418 (geneticin) treatment. Tandem purification of 
the readthrough products utilized C-terminal Strep or FLAG tags, followed by selection 
for the N-terminal HA tag. Briefly, cells were harvested in lysis buffer (FLAG purification: 
0.025 M Tris, pH 7.4, 0.15 M NaCl, 0.001 M EDTA, 1% NP40, 5% glycerol; StrepTactin 
purification:100 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA) and the clarified lysates 
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were bound to either StrepTactin (Qiagen) or FLAG (Sigma) magnetic beads at 4oC 
overnight according to the manufacturer’s protocol. The eluates from the first purification 
were then bound to anti-HA magnetic beads for one hour and eluted by boiling the beads 
in 1X Laemmli Buffer (BioRad) for 10 min. The elution profile was monitored by measuring 
luciferase activity at each step in the purification process, using Bright-Glo (Promega) as 
a substrate and measured using a Perkin Elmer EnVision plate reader. The purified 
readthrough products were then analyzed on 10% SDS-PAGE, and gels were then silver 
stained (ProteoSilver, Sigma) and processed for mass spectrometry. At least three 
independent experiments were performed for each condition (each codon under one 
specific readthrough-inducing condition).  
 iii. Purification of GFP-CFTR readthrough products. 293H cells were harvested 
and lysed using three freeze and thaw cycles and a lysis buffer (pH 8.0, 50 mM NaH2PO4, 
300 mM NaCl, 10 mM imidazole) containing a protease inhibitor cocktail tablet (Roche). 
The lysate was centrifuged and the supernatant was transferred to a new tube and 
incubated with Ni-NTA Superflow resin (Qiagen) overnight at 4ºC. The next day, the resin 
was washed three times with lysis buffer and eluted with elution buffer (pH 8.0, 50 mM 
NaH2PO4, 300 mM NaCl, 500 mM imidazole) four times. 
b) Western analyses 
 i. Luciferase polypeptides. For detection of the readthrough products, 293H 
whole-cell lysates were electrophoresed through 10% (w/v) Bis-Tris polyacrylamide gels 
(ThermoFisher Technologies), transferred to a nitrocellulose membrane (BioRad), and 
incubated with anti-HA (1:1,000; ThermoFisher Technologies), anti-FLAG (1:1,000; 
Sigma), or anti- Firefly Luciferase (1:2,000; Rockland) antibodies. An anti-GAPDH 
antibody (1:10,000; Abcam) was used for normalization.  
 ii. GFP polypeptides. For the TGFP readthrough reporters, 293H cells were 
washed with 1X PBS, harvested, and lysed with lysis buffer. The lysate was centrifuged, 
boiled,   and fractionated by electrophoresis on SDS-PAGE gels. Gels were transferred 
to Immobilon-FL PVDF membranes (EMD Millipore), which were then blocked using 5% 
(w/v) milk in PBST (0.3% Tween 20, v/v), incubated with anti-HA (Covance Research), 
anti-Tubulin (Abcam or DHSB), and anti-TGFP (Pierce) antibodies, followed by incubation 
with secondary antibodies IRDye 680RD and IRDye 800CW (Li-Cor) before imaging 
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using a Li-Cor Odyssey® CLx Infrared Imaging System. For CFTR western blots, cells 
were lysed with RIPA buffer containing a protease inhibitor tablet (Roche). The lysate was 
collected, incubated at 37°C for 30 min before electrophoresis, and then transferred and 
blotted as was done for TGFP proteins. CFTR antibodies were a 1:1 mixture of #570 and 
#596 monoclonal anti-CFTR antibodies from the University of North Carolina 
(http://www.unc.edu/~tjjensen/CFADP/index.html). 
 For the H2B-GFP readthrough products, 293H cell lysates were electrophoresed 
through 10% (w/v) Bis-Tris polyacrylamide gels (ThermoFisher Technologies), 
transferred to a nitrocellulose membrane (BioRad), and incubated with anti-GFP (1:1,000; 
Life Science Technologies) antibodies. An anti-GAPDH antibody (1:10,000; Abcam) was 
used for normalization.  
 iii. p53 polypeptides. The p53 readthrough products from cell lines expressing 
p53 nonsense alleles were detected using p53 MSD/ELISA (Meso Scale Discovery) using 
DO1 SC-126X (SantaCruz) and ab59243 (Abcam).   
c) RNA analyses 
 i. LUC transcripts. Total RNA was extracted using RNeasy Mini Kit (Qiagen) as 
per the manufacturer’s instructions. cDNA was synthesized using SuperScript III reverse 
transcriptase (Invitrogen). RNA samples were analyzed by Taqman-based RT-qPCR 
using luciferase specific primers (Table S7). 
 ii. GFP transcripts. Total RNA was extracted using RNeasy Mini Kit (Qiagen) as 
per the manufacturer’s directions. cDNA was obtained through reverse transcription using 
iScript™ Reverse Transcription Supermix (Biorad). Quantitative real-time PCR was 
performed using the CFX96 Real-Time PCR Detection System (Biorad). Primer 
efficiencies for human CFTR discovered in Primerbank 
(http://pga.mgh.harvard.edu/primerbank/index.html) (5’-CCTATGACCC GGATAACAAG 
GA-3’ and 5’-GAACACGGCT TGACAGCTTT A-3’) and rat tubulin15 (5'-CAACACCTTC 
TTCAGTGAGA CAGG-3' and 5'-TCAATGATCT CCTTGCCAAT GGT-3’) were 93.4% 
and 95.8%, respectively. 
d) Functional assays in FRT monolayers 
 CFTR constructs were transfected into Fischer Rat Thyroid (FRT) cells and cell 
lines that stably express each CFTR cDNA were selected.  Cells were seeded on Costar 
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24 well 0.4 µM permeable supports (Corning). After four days, confluent monolayers with 
tight junctions had formed, as measured by transepithelial resistance using an epithelial 
volt-ohm meter (WPI). Isc was measured in Ussing Chambers (Physiologic Instruments) 
using an 8-channel voltage clamp, while Gt was measured using a 24-channel voltage 
clamp (6). 
 
Sample Preparation for Mass Spectrometry Analyses 
a) Analyses of luciferase readthrough products. Full-length luciferase readthrough 
products resolved on SDS-polyacrylamide gels were excised after silver staining and the 
destained gel slices were subjected to endoproteinase Lys-C (Roche Diagnostics) 
digestion followed by LC-MS/MS analyses as described previously (1). Raw data files 
were subjected to database searching with Mascot Server (version 2.5) against the 
SwissProt index of S. cerevisiae (for yeast samples) and Human (for mammalian 
samples) that contain the sequences of all 20 potential codon 20 mutations of the LUC 
gene. The relative abundance of each amino acid at position 20 of luciferase was 
calculated by adding the corresponding precursor intensity of individual endo Lys-C 
peptides containing a codon 20 amino acid to yield a total peptide abundance that was 
then used to calculate the percentage of insertion of each amino acid (1). 
b) Analyses of GFP-CFTR readthrough products. Full-length TGFP was purified using 
Ni-NTA Superflow resin (Qiagen). Protein fractions were resolved on an SDS Bis-Tris gel 
(Invitrogen) and gel bands corresponding to the molecular weight of interest were 
reduced, carbidomethylated, dehydrated, and digested with Trypsin Gold (Promega). 
Peptides were extracted, concentrated under vacuum, and resolubilized in 0.1% formic 
acid prior to analysis by 1D reverse phase LC-ESI-MS2 (7). Peptide digests were injected 
onto a Surveyor HPLC plus (Thermo Scientific) using a split flow configuration on the 
back end of a Jupiter C-18 column (Phenomenex). This system runs in-line with a Thermo 
Orbitrap Velos Pro hybrid mass spectrometer, equipped with a nano-electrospray source 
(Thermo Scientific), and all data were collected in CID mode. Data were searched using 
SEQUEST with a precursor mass window of 20ppm, trypsin digestion, variable 
modification C at 57.0293, and M at 15.9949. Searches were performed with a human 
subset of the UniRef100 database, which included common contaminants such as 
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digestion enzymes and human keratin, in addition to sequences specific to these 
experiments. A list of peptide IDs was generated based on SEQUEST search results, and 
which was then filtered using Scaffold Q+ (Protein Sciences). The filter cut-off values 
were set with peptide length (>5 AA’s), no peptides with a MH+1 charge state were 
included, peptide probabilities were calculated and set to >90% C.I., with the number of 
peptides per protein set at two or more, and protein probabilities set to >99% C.I. Relative 
quantification across experiments was performed via spectral counting, and spectral 
count abundances were then normalized between samples. All spectra covering the 
sequences of interest were manually interpreted as a final quality control. 
 
PTC124-AMP 
a) Synthesis of PTC124-AMP. The compound was prepared as described by Auld et al. 
(8) (see their SI methods, compound 6). Briefly, a mixture of 3-(5-(2-fluorophenyl)-1,2,4-
oxadiazol-3-yl)benzoic acid (0.2 g (0.70 mM) and ethyl-(N’,N’-dimethylamino) 
propylcarbodiimide (EDC) 0.67 g (3.52 mM) in anhydrous DMF (4 mL) was stirred at room 
temperature for 10 min. Then adenosine-5-monophophate disodium salt 0.275 g (0.70 
mM) and 4-dimethylamino-pyridine (DMAP) 9 mg (0.07 mM) were added and stirred 
vigorously at room temperature for one hour. The crude product was purified by 
preparative HPLC and lyophilized to get the free acid as a white powder. The free acid 
was then dissolved in 0.1 M ammonium bicarbonate solution and lyophilized to obtain the 
ammonium salt of the PTC124-AMP adduct. 
b) Stability of PTC124-AMP.  The stability of PTC124-AMP was assessed under 
conditions previously described for a cell-free translation system (9) except that 293H 
cells were used to prepare the lysate. Synthetic LUC mRNA containing a PTC at position 
190 was prepared using the MegaScript in vitro transcription kit (Ambion, Austin, TX). 
The reaction mixtures (20 µl) contained 16.5 mM HEPES (KOH) pH 7.4, 85 mM 
potassium acetate, 1.48 mM magnesium acetate, 0.56 mM ATP, 0.075 mM GTP, 18.75 
mM creatine phosphate (di-Tris), 1.275 mM dithiothreitol (DTT), amino acids, creatine 
kinase, cell extract (60% of the reaction volume), 100 ng RNA, and 0.25% DMSO. Stock 
solutions of PTC124 (ataluren) and PTC124-AMP were prepared in 100% DMSO and 
PTC124-AMP at a final concentration of 5uM was added to the in vitro reaction. At various 
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time points following the addition of PTC124-AMP, aliquots were removed and the levels 
of PTC124-AMP and PTC124 (ataluren) were determined by LC/MS-MS.  
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Supplementary figure legends 
 
Fig. S1. Key features of reporter genes expressed in yeast and mammalian cells.  
(A) The yeast HA-HIS3(UAA100)-SF reporter contained an in-frame 3X HA tag at the N-
terminus of its ORF, adjacent StrepII and FLAG (SF) tags at the ORF C-terminus. (B) The 
NanoLuc reporter for mammalian cells that encoded a UGA stop codon at ORF position 
12 (W12X). (C) The construction of four distinct yeast LUC alleles, one wild-type and 
three with each of the possible PTCs inserted at codon 20 of the LUC ORF, was described 
previously (1). The HA-LUC(PTC20)-SF reporter set for expression in 293H cells was similar 
to that used in yeast (1), but contained an intron insertion (site denoted in figure). (D) The 
Turbo GFP-CFTR-G542X reporter used to identify amino acids inserted at the PTC during 
readthrough. The CFTR context included in the construct is shown. (E) The H2B-GFP 
reporter originally described by Lentini et al. (2). (F) The p53 reporters used to detect 
ataluren-mediated readthrough encode the p53 ORF with UGA at codons 196 or 213. 
 
Fig. S2. Nonsense-containing reporter transcripts are substrates for NMD. 
Northern analyses of the (A) HA-LUC(PTC20)-SF and (B) HA-HIS3(UAA100)-SF mRNAs 
expressed in wild-type [PSI-] yeast cells without/with drug treatment and in upf1 cells 
(as a control). Blots were re-probed for CYH2 transcripts as an internal NMD control. 
SCR1 RNA was used as a loading control. (C) RT-qPCR analyses of HA-LUC-SF wild-
type and nonsense-containing mRNAs in 293H cells after cycloheximide treatment, 
showing drug-dependent stabilization of the transcripts derived from PTC alleles.  
 
Fig. S3. Readthrough efficiencies of different reporters expressed in mammalian 
cells. (A) Ataluren and G418 increase readthrough of the p53-UGA-196 allele in CALU-
6 cells and the p53-UGA-213 allele in HDQ cells. The respective reporters are shown in 
Fig. S1 and the data depict fold increase over DMSO as quantified by MSD/ELISA (n=3). 
(B) Ataluren and G418 increase readthrough from the H2B-GFP-UGA58 reporter depicted 
in Fig. S1. Western blot of readthrough products in transiently transfected 293H cells. 
H2B-GFP is the full-length product expressed from a construct lacking a PTC. (C) 
Readthrough efficiency measured as luciferase activity from HA-LUC-SF and HA-
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LUC(PTC20)-SF reporters expressed in 293H cells (n=3; error bars represent standard 
deviation from the mean). (D) Western analyses showing full-length readthrough products 
expressed from HA-LUC(UGA20)-SF reporters after ataluren or G418 treatment of 293H 
cells.  
 
Fig. S4. Ataluren treatment of yeast cells promotes readthrough of HA-LUC(PTC20)-
SF reporter mRNA. Western analyses showing full-length readthrough products 
expressed from HA-LUC(UGA20)-SF reporters after ataluren or G418 treatment.  
 
Fig. S5. Half-life of the His3 protein. 
Top: representative western blot depicting decay of the WT His3 protein after 
cycloheximide treatment of yeast cells at t=0. Bar graphs: upper and middle panels depict 
quantitation of results from untreated and cycloheximide-treated cultures expressing wild-
type His3 protein; lower panel depicts quantitation of full-length His3 protein derived from 
ataluren-mediated readthrough after cycloheximide treatment of yeast cells at t=0. The 
levels of wild-type or PTC readthrough His3 protein were determined by western blotting 
and normalized to levels of the Pgk1 protein also determined by western blotting in the 
same experiments. T15, 30, 45, 60=15, 30, 45, and 60 min after cycloheximide addition. 
 
Fig. S6. PTC124-AMP is rapidly converted to the active readthrough molecule 
PTC124 (ataluren) in an in vitro translation extract. PTC124-AMP at a final 
concentration of 5uM was added to an in vitro readthrough assay. At various time points 
following the addition of PTC124-AMP (dissolved in DMSO), aliquots were removed and 
the levels of PTC124-AMP and PTC124 (ataluren) were determined by LC/MS-MS.  
 
Fig. S7. Purification of luciferase readthrough products. 
 (A) Western blot analysis of the full-length readthrough products purified on Strep-Tactin 
resin from wild-type [PSI-] yeast cells after treatment with ataluren. Anti-FLAG antibody 
was used for detection. Ec depicts elution fractions (E3-E7) that were pooled and 
concentrated. (B) Silver-stained SDS/PAGE gel showing the results of FLAG - HA 
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purification of the luciferase readthrough protein (marked with an asterisk) from ataluren-
treated 293H cells expressing the HA-LUC(UGA20)-SF reporter. 
 
Fig. S8. Ataluren-induced His3 and luciferase readthrough products are functional. 
(A) Growth of wild-type cells expressing the HA-HIS3(UAA100)-SF allele in media lacking 
histidine with or without drug treatment. (B) Luciferase activity from HA-LUC-SF reporter 
with missense mutations introduced at position 20 of luciferase. Luciferase activity is 
expressed as relative luciferase units/µg of protein (n=3; error bars represent standard 
deviation from the mean). 
 
Fig. S9. Representative mass spectrometry spectra in CFTR G542WT and G542X 
samples. Tandem MS2 spectra are illustrated for the CFTR wild-type tryptic peptides and 
those from three CFTR mutants analyzed in our study; (A) G542G; (B) G542R; (C) 
G542W; and (D) G542C. 
 
Fig. S10. tRNA overexpression analyses. (A) Northern analyses of total RNA isolated 
under acidic conditions from wild-type cells and cells overexpressing tRNA-Arg-UCU or 
tRNA-Arg-UCG. After polyacrylamide gel electrophoresis and transfer, blots were probed 
for tRNA-Arg using a 32P-labeled oligonucleotide. The blots were re-probed for tRNA-Glu 
as a control for equal loading. Lane 1: Wild-type; Lane 2: Wild-type + HA-LUC(UGA20)-SF; 
Lane 3: Wild-type + HA-LUC(UGA20)-SF + tRNA-Arg-UCU; Lane 4: Wild-type + HA-
LUC(UGA20)-SF + tRNA-Arg-UCG. (B) Readthrough efficiency measured as luciferase 
activity from the HA-LUC(UGA20)-SF reporter from wild-type [PSI-] cells or cells 
overexpressing either tRNA-Arg-UCU or tRNA-Arg-UCG. Luciferase activity is expressed 
as relative luciferase units/µg of protein/RNA units (n=3; error bars represent standard 
deviation from the mean). Lane 1: Wild-type + HA-LUC(UGA20)-SF; Lane 2: Wild-type + HA-
LUC(UGA20)-SF + tRNA-Arg-UCU; Lane 3: Wild-type + HA-LUC(UGA20)-SF + tRNA-Arg-
UCG; Lane 4:  Wild-type + HA-LUC-SF. (C) Comparison of amino acid insertion at UGA 
during termination readthrough of HA-LUC(UGA20)-SF reporter in yeast cells with either 
endogenous levels tRNA-Arg-UCU, or  overexpression of tRNA-Arg-UCU or tRNA-Arg-
UCG. HA-Luc(PTC20)-SF proteins purified from yeast cells were subjected to mass 
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spectrometry analyses. The numbers denote the frequency (+ standard deviation of the 
mean) of insertion of the amino acids at UGA (n=3). The type and the position of 
mispairing in the codon are depicted for each amino acid inserted. (D) Northern blot 
analyses of total RNA isolated under acidic conditions from wild-type yeast cells and cells 
overexpressing tRNA-Glu-UUC. After polyacrylamide gel electrophoresis and transfer, 
blots were probed for tRNA-Glu using a 32P-labeled oligonucleotide. The blots were re-
probed for tRNA-Arg-UCU as a control for equal loading. Lanes 1-3 were all derived from 
the same gel. (E) Readthrough efficiency measured as luciferase activity from the HA-
LUC(UAA20)-SF reporter in wild-type yeast cells and cells overexpressing tRNA-Glu-UUC. 
Luciferase activity is expressed as relative luciferase units/µg of protein/RNA units (n=3; 
error bars represent standard deviation from the mean). (F) Amino acids inserted at UAA 
during termination readthrough in yeast cells overexpressing tRNA-Glu-UUC. HA-
LUC(UAA20)-SF protein products were purified and subjected to mass spectrometry 
analyses. The numbers denote the average frequency of insertion of the amino acids at 
UAA (from two independent experiments).  
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Table S1. Amino acids inserted at PTCs after treatment of wild-type [PSI-] yeast cells with 7.5 µM G418.  
Codon Amino acid inserted Frequency of insertion (%) Mispairing event 
Experiment 1 Experiment 2 
UAA Tyr 51.1 52.6 Position 3 (A-G) 
 Gln 46.9 45.4 Position 1 (U-G) 
 Lys 1.1 2.0 Position 1(U-U) 
     
UAG Tyr 1.59 1.55 Position 3 (G-G) 
 Gln 4.35 5.1 Position 1 (U-G) 
 Lys 90.9 90.8 Position 1(U-U) 
 Trp 1.55 0.85 Position 2 (A-C) 
 Arg 0.87 0.79 Non-cognate tRNA employing position 1 (U-G) 
and position 2 (A-C) mispairing  
 Cys 0.26 0.18 Non-cognate tRNA employing position 2 (A-C) 
 
 Ser 0.02 0.02 Position 2 (A-G); Non-cognate tRNA employing 
position 2 (A-G) and position 3 (G-A/G-G/G-U) 
mispairing 
 Gly 0.18 0.53 Non-cognate tRNA employing position 1(U-C) and 
position 2 (A-C) mispairing 
 Glu 0.03 0.03 Position 1 (U-C); Non-cognate tRNA employing 
position 1 (U-C) and position 3 (G-U) mispairing 
 Thr 0.11 0.08 Non-cognate tRNA employing position 1(U-U) and 
position 2 (A-G) mispairing 
 Phe 0.02 0 Non-cognate tRNA employing position 2(A-A) and 
position 3 (G-A/G-G) mispairing 
 Val 0 0.02 Non-cognate tRNA employing position 1(U-C) and 
position 2 (A-A) mispairing 
     
UGA Trp 61.0 57.3 Position 3 (A-C) 
 Arg  16.2 Position 1 (U-U) 
 Cys 27.9 26.5 Position 3 (A-G) 
 
position 3 (G-A/G-G) mispairing 
11.0
Codon Amino acid inserted Frequency of insertion (%) Mispairing event 
UAA Tyr 72.9 Position 3 (A-G) 
 Gln 24.2 Position 1 (U-G) 
 Lys 2.5 Position 1(U-U) 
 His 0.16 Non-cognate tRNA employing position 1 (U-G) 
and position 2 (A-A/A-G) mispairing 
 Trp 0.11 Non-cognate tRNA employing position 1 and 2 (A-
C) mispairing 
    
UAG Tyr 2.25 Position 3 (G-G) 
 Gln 4.36 Position 1 (U-G) 
 Lys 90.5 Position 1(U-U) 
 Trp 0.98 Position 2 (A-C) 
 Arg 0.81 Non-cognate tRNA employing position 1 (U-G) 
and position 2 (A-C) mispairing  
 Cys 0.39 Non-cognate tRNA employing position 2 (A-C) 
and position 3 (G-G/G-A) mispairing 
 Ser 0.05 Position 2 (A-G); Non-cognate tRNA employing 
position 2 (A-G) and position 3 (G-A/G-G/G-U) 
mispairing 
 Gly 0.42 Non-cognate tRNA employing position 1(U-C) and 
position 2 (A-C) mispairing 
 Glu 0.02 Position 1 (U-C); Non-cognate tRNA employing 
position 1 (U-C) and position 3 (G-U) mispairing 
 Thr 0.15 Non-cognate tRNA employing position 1(U-U) and 
position 2 (A-G) mispairing 
 Val 0.02 Non-cognate tRNA employing position 1(U-C) and 
position 2 (A-A) mispairing 
    
UGA Trp 47.9 Position 3 (A-C) 
 Arg 26.1 Position 1 (U-U) 
 Cys 24.4 Position 3 (A-G) 
 Tyr 0.81 Non-cognate tRNA employing position 2 (G-U) 
and position 3 (A-A/A-G) mispairing 
 Lys 0.56 Non-cognate tRNA employing position 1 (U-U) 
and position 2 (G-U) mispairing 
Table S2. Amino acids inserted at PTCs after treatment of wild-type [PSI-] yeast cells with 15 µMG418.  
Codon 
Position 
Mispaired 
tRNA 
sequence 
(3'-5’) 
AA 
encoded 
BP 
created  
1 
UAA 
UUU Lys U-U 
UUG Gln U-G 
UUC Glu U-C 
UUA STOP U-A 
2 
UAA 
UUA STOP A-U 
UGA Ser A-G 
UCA STOP A-C 
UAA Leu A-A 
3 
UAA 
UUA Stop A-U 
GUA 
Tyr 
A-G 
AUA A-A 
CUA Stop A-C 
Codon 
Position 
Mispaired 
tRNA 
sequence 
(5-3’) 
AA 
encoded 
BP 
created  
1 
UAG 
CUU Lys U-U 
CUG Gln U-G 
CUC Glu U-C 
CUA STOP U-A 
2 
UAG 
CUA STOP A-U 
CGA Ser A-G 
CCA Trp A-C 
CAA Leu A-A 
3 
UAG 
UUA STOP G-U 
GUA 
Tyr 
G-G 
AUA G-A 
CUA Stop G-C 
Codon 
Position 
Mispaired 
tRNA 
sequence 
(5’-3’) 
AA 
encoded 
BP 
created  
1 
UGA 
UCU 
Arg 
U-U 
UCG U-G 
UCC Gly U-C 
UCA Stop U-A 
2 
UGA 
UUA Stop G-U 
UGA Ser G-G 
UCA Stop G-C 
UAA Leu G-A 
1 
UGA 
UCA Stop A-U 
GCA 
Cys 
A-G 
ACA A-A 
CCA Trp A-C 
Table S3. Possible codon-anticodon base pairings during PTC readthrough.
Codon 
Position
Mispaired tRNA 
sequence (5’-3’)
AA encoded BP created  Gentamicin 
(average + stdev)
UCU U-U
UCG U-G
UCC Gly U-C
UCA Stop U-A
UUA Stop G-U
UGA Ser G-G
UCA Stop G-C
UAA Leu G-A
UCA Stop A-U
GCA A-G
ACA A-A
CCA Trp A-C 24.2+3
48.4+6.8
27.0+9.8
1
UGA
Arg
2
UGA
1
UGA Cys
Table S4. Amino acids inserted at UGA after treatment of HEK293cells with Gentamicin. 
Sample Peptide Sequence m/z (z, ppm) RT (min) R-NSC             Exp 1
R-NSC             
Exp 2 Ave R-NSC
WT GSPHIVLGEGGLVPR 496.62 (3, -0.36) 66.5 100 100 100
G542X GSPHIVLR 439.76 (2, 0.20) 41.2 26 15 20
GSPHIVLCEGGLVPR      
(IAA modified) 530.95 (3, -0.15) 67.4 41 46 44
GSPHIVLWEGGLVPR 539.64 (3, 0.16) 81.9 33 38 36
Table S5. Amino acids inserted at G542X after treatment of HEK293 cells with G418
Table S6. Amino acids inserted at PTCs after treatment of 293H cells with ataluren or G418. 
Codon Position Mispaired tRNA sequence (3'-5’)
AA 
encoded BP created DMSO DMSO DMSO Ataluren Ataluren Ataluren G418 G418 G418
DMSO 
average ± stdev
Ataluren 
average ± stdev
G418 
average ± stdev
1
UAA
UUU Lys U-U
UUG Gln U-G 23.4 32.6 41.2 39.2 51.9 28.6 37 53.6 65.3 32.4 ± 8.9 39.9 ± 11.7 52 ± 14.2
UUC Glu U-C
UUA STOP U-A
2
UAA
UUA STOP A-U
UGA Ser A-G
UCA STOP A-C
UAA Leu A-A
3
UAA
UUA Stop A-U
GUA
Tyr
A-G 76.5 67.3 58.7 59.9 45.7 68.1 62.7 46.4 34.6 67.5 ± 8.9 57.9 ± 11.3 47.9 ± 14.1AUA A-A
CUA Stop A-C
Codon Position Mispaired tRNA sequence (5-3’)
AA 
encoded BP created DMSO DMSO DMSO DMSO Ataluren Ataluren Ataluren Ataluren Ataluren Ataluren G418 G418 G418 G418
DMSO 
average ± stdev
Ataluren
average ± stdev
G418 
average ± stdev
1
UAG
CUU Lys U-U 3 1.1 1.5 2.2 2.0 ± 0.8
CUG Gln U-G 34.9 39 15 11.9 81.4 33.7 30.2 81.4 45.1 47.3 80 97.7 87.9 80.5 25.2 ± 13.7 53.2 ± 20.3 86.5 ± 8.3
CUC Glu U-C
CUA STOP U-A
2
UAG
CUA STOP A-U
CGA Ser A-G
CCA Trp A-C 2.4 2.6 0.19 2.1 0.49 0.2 1.7 4.9 1.2 1.3 ± 1.4 1.8 ± 1.9
CAA Leu A-A
3
UAG
UUA STOP G-U
GUA
Tyr
G-G 61.6 58.8 84 87.8 15.6 64.2 69.3 15.7 48.9 49.9 16 1.1 10.1 16 73.1 ± 15.0 43.9 ± 20.9 10.8 ± 7.0AUA G-A
CUA Stop G-C
Codon Position Mispaired tRNA sequence (5’-3’)
AA 
encoded BP created DMSO DMSO DMSO Ataluren Ataluren Ataluren Ataluren Ataluren G418 G418 G418 G418
DMSO 
average ± stdev
Ataluren 
average ± stdev
G418 
average ± stdev
1
UGA
UCU
Arg
U-U 56 60.5 59.24 63.7 65.3 57.5 86 76 51.7 66.7 79.7 60 58.6 ± 2.3 69.7 ±11.3 64.5 ± 11.8UCG U-G
UCC Gly U-C
UCA Stop U-A
2
UGA
UUA Stop G-U
UGA Ser G-G
UCA Stop G-C
UAA Leu G-A
1
UGA
UCA Stop A-U
GCA
Cys
A-G 0.5 0.5 2 0.06 0.2 28.8 11.2 12.4 18.3 0.7 ± 0.78 17.7 ± 8.0ACA A-A
CCA Trp A-C 44 39.5 40.76 35.7 34.2 40.2 13 21 19.5 22.1 7.8 22 41.4 ± 2.3 28.8 ± 11.4 17.9 ± 6.8
Table S7. Oligonucleotides used in this study.
Position 20 Arg For CTACCCACTCGAAGACAGAACCGCCGGCGAGCAG
Position 20 Arg Rev CTGCTCGCCGGCGGTTCTGTCTTCGAGTGGGTAG
Position 20 Trp For CTACCCACTCGAAGACTGGACCGCCGGCGAGCAG
Position 20 Trp Rev CTGCTCGCCGGCGGTCCAGTCTTCGAGTGGGTAG
Position 20 Cys For CTACCCACTCGAAGACTGCACCGCCGGCGAGCAG
Position 20 Cys Rev CTGCTCGCCGGCGGTGCAGTCTTCGAGTGGGTAG
Position 20 Tyr For CTACCCACTCGAAGACTACACCGCCGGCGAGCAG
Position 20 Tyr Rev CTGCTCGCCGGCGGTGTAGTCTTCGAGTGGGTAG
Position 20 Lys For CTACCCACTCGAAGACAAAACCGCCGGCGAGCAG
Position 20 Lys Rev CTGCTCGCCGGCGGTTTTGTCTTCGAGTGGGTAG
Position 20 Gln For CTACCCACTCGAAGACCAAACCGCCGGCGAGCAG
Position 20 Gln Rev CTGCTCGCCGGCGGTTTGGTCTTCGAGTGGGTAG
For= Forward primer 
Rev= Reverse primer
DB4084 CGTTGGGGACTGACGACAGACAGCC
DB4085 GGCTGTCTGTCGTCAGTCCCCAACG
